Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer Statistics, 2021.CA Cancer J Clin. 2021; 71: 7-33
- Epidemiology of Prostate Cancer.World J Oncol. 2019; 10: 63-89
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.JAMA Oncol. 2019; 5: 1749-1768
- A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.Eur Urol. 2019; 76: 43-51
- Prostate-cancer mortality at 11 years of follow-up.N Engl J Med. 2012; 366: 981-990
- Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.Lancet. 2014; 384: 2027-2035
- Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2018; 319: 1914-1931
- Overdiagnosis and overtreatment of prostate cancer.Eur Urol. 2014; 65: 1046-1055
- Systematic review of complications of prostate biopsy.Eur Urol. 2013; 64: 876-892
- Prostate Cancer Early Detection Guidelines.(Available at:) (Accessed July 22, 2022)
- Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.Cochrane Database Syst Rev. 2019; 4: CD012663
- Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2022; 25: 174-179
- Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.Eur Urol. 2020; 78: 402-414
- Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions.Transl Androl Urol. 2021; 10: 3091-3103
- 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.Urol Clin North Am. 2016; 43: 39-46
- Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.Eur Urol. 2015; 68: 207-213
- Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.J Urol. 2018; 199: 1470-1474
- Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.PLoS One. 2018; 13: e0201384
- A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.Eur Urol. 2015; 68: 464-470
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.Lancet. 2017; 389: 815-822
- Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI.Urol Oncol. 2019; 37: 672-677
- Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.Eur Urol Oncol. 2020; 3: 700-704
- Clinical Utility of 4Kscore((R)), ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer.J Urol. 2021; 205: 452-460
- A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.JAMA Oncol. 2016; 2: 882-889
- A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.Eur Urol. 2018; 74: 731-738
- Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.Int J Urol. 2021; 28: 47-52
- Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men.J Urol. 2015; 194: 65-72
- Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.Eur Urol. 2015; 68: 139-146
- Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy.Prostate. 2015; 75: 103-111
- A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.Eur Urol. 2019; 75: 558-561
- United States Food and Drug Administration. 2022.(Available at:) (Accessed July 22, 2022)
- The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.Sci Rep. 2016; 6: 35364
- Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.Prostate Cancer Prostatic Dis. 2017; 20: 228-233
- Performance of prostate health index and PSA density in a diverse biopsy-naive cohort with mpMRI for detecting significant prostate cancer.BJUI Compass. 2021; 2: 370-376
- The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer.Sci Rep. 2021; 11: 1286
- Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.J Urol. 2019; 202: 256-263
- SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.Cancers (Basel). 2021; 13
- Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.World J Urol. 2021; 39: 1869-1877
- Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naive men.Prostate Cancer Prostatic Dis. 2021; 24: 1110-1119
- Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.Eur Urol. 2022; 81: 124-125
- Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.Eur Urol. 2016; 70: 45-53
- Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.J Urol. 2021; 205: 732-739
- Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need.Urology. 2022; 164: 184-190
- Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.BMJ. 2016; 352: i6
- Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.Transl Androl Urol. 2018; 7: 132-144
- Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.Cancer. 2016; 122: 884-892
- Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.Eur Urol. 2014; 66: 22-29
- Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.Eur Urol. 2018; 73: 353-360
- MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?.Transl Androl Urol. 2018; 7: 70-82
- Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.Urol Oncol. 2020; 38: 846.e9-846.e16
Article info
Footnotes
Competing Interests: J.J. Tosoian is a cofounder of LynxDx, Inc. The other authors declare no competing interests.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
